These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36883100)

  • 1. Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: A pharmacogenomics Egyptian study.
    Amin NS; Abd El-Aziz MK; Hamed M; Moustafa RR; El Tayebi HM
    Front Immunol; 2023; 14():1087595. PubMed ID: 36883100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of LncRNA Linc00513 Containing Lupus-Associated Genetic Variants as a Novel Regulator of Interferon Signaling Pathway.
    Xue Z; Cui C; Liao Z; Xia S; Zhang P; Qin J; Guo Q; Chen S; Fu Q; Yin Z; Ye Z; Tang Y; Shen N
    Front Immunol; 2018; 9():2967. PubMed ID: 30619325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.
    Vandenbroeck K; Matute C
    Pharmacogenomics; 2008 May; 9(5):639-45. PubMed ID: 18466107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?
    Carlson RJ; Doucette JR; Knox K; Nazarali AJ
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):249-61. PubMed ID: 25524087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in proinflammatory cytokines genes and susceptibility to Multiple Sclerosis.
    Bakr NM; Hashim NA; El-Baz HAE; Khalaf EM; Elharoun AS
    Mult Scler Relat Disord; 2021 Jan; 47():102654. PubMed ID: 33302229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.
    Grossman I; Knappertz V; Laifenfeld D; Ross C; Zeskind B; Kolitz S; Ladkani D; Hayardeny L; Loupe P; Laufer R; Hayden M
    Prog Neurobiol; 2017 May; 152():114-130. PubMed ID: 26952809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.
    Hajian S; Mazdeh M; Nouri F; Roshanaei G; Soleimani M
    Mol Biol Rep; 2021 Aug; 48(8):6007-6013. PubMed ID: 34328599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Multiple Sclerosis Phenotypes with Single Nucleotide Polymorphisms of
    Al-Eitan L; Qudah MA; Qawasmeh MA
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single nucleotide variants around the connective tissue growth factor (CTGF/CCN2) gene and their association with multiple sclerosis risk, disability scores, and rate of disease progression.
    Can Demirdöğen B; Kılıç OO; Karagülle EN; Kalmaz LM; Mungan S
    Neurol Sci; 2022 Jun; 43(6):3867-3877. PubMed ID: 35091888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in the CIITA -168A/G (rs3087456) and CIITA +1614G/C (rs4774) may influence severity in multiple sclerosis patients.
    Pereira VCSR; Fontes-Dantas FL; Paradela ER; Malfetano FR; Scherpenhuijzen SSB; Mansur LF; Luiz RR; Oliveira AP; Farinhas JGD; Maiolino Â; Alves-Leon SV
    Arq Neuropsiquiatr; 2019 Mar; 77(3):166-173. PubMed ID: 30970129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.
    Vandenbroeck K; Comabella M
    J Interferon Cytokine Res; 2010 Oct; 30(10):727-32. PubMed ID: 20836710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis.
    Carrasco-Campos MI; Pérez-Ramírez C; Macías-Cortés E; Puerta-García E; Sánchez-Pozo A; Arnal-García C; Barrero-Hernández FJ; Calleja-Hernández MÁ; Jiménez-Morales A; Cañadas-Garre M
    Mol Neurobiol; 2021 Sep; 58(9):4716-4726. PubMed ID: 34169444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.
    Kulakova O; Bashinskaya V; Kiselev I; Baulina N; Tsareva E; Nikolaev R; Kozin M; Shchur S; Favorov A; Boyko A; Favorova O
    Pharmacogenomics; 2017 Nov; 18(17):1563-1574. PubMed ID: 29095108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.
    Ross CJ; Towfic F; Shankar J; Laifenfeld D; Thoma M; Davis M; Weiner B; Kusko R; Zeskind B; Knappertz V; Grossman I; Hayden MR
    Genome Med; 2017 May; 9(1):50. PubMed ID: 28569182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.
    Cunningham S; Graham C; Hutchinson M; Droogan A; O'Rourke K; Patterson C; McDonnell G; Hawkins S; Vandenbroeck K
    Clin Pharmacol Ther; 2005 Dec; 78(6):635-46. PubMed ID: 16338279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of non-HLA single nucleotide polymorphisms in multiple sclerosis susceptibility.
    Bahreini SA; Jabalameli MR; Saadatnia M; Zahednasab H
    J Neuroimmunol; 2010 Dec; 229(1-2):5-15. PubMed ID: 20832869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.